-
-
-
-
-
-
-
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
-
-
-
-
-
-
-
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
-
-
-
-
-
-
-
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
-
-
-
-
-
-
-
LumiraDx Reports Second Quarter 2022 Results
-
-
-
-
-
-
-
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
-
-
-
-
-
-
-
LumiraDx (LMDX) Prices $56.5M Convertible Notes Offering
-
-
-
-
-
-
-
LumiraDx CRP Test Achieves CE Marking
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

